JP2004525988A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004525988A5 JP2004525988A5 JP2002588889A JP2002588889A JP2004525988A5 JP 2004525988 A5 JP2004525988 A5 JP 2004525988A5 JP 2002588889 A JP2002588889 A JP 2002588889A JP 2002588889 A JP2002588889 A JP 2002588889A JP 2004525988 A5 JP2004525988 A5 JP 2004525988A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- polypeptide
- epidermolysis bullosa
- skin
- blisters
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 49
- 206010014989 Epidermolysis bullosa Diseases 0.000 claims 16
- 229920001184 polypeptide Polymers 0.000 claims 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims 16
- 230000007850 degeneration Effects 0.000 claims 8
- 230000003628 erosive effect Effects 0.000 claims 8
- 230000002265 prevention Effects 0.000 claims 8
- 230000035876 healing Effects 0.000 claims 7
- 230000001629 suppression Effects 0.000 claims 6
- UGPMCIBIHRSCBV-XNBOLLIBSA-N Thymosin beta 4 Chemical compound N([C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(C)=O UGPMCIBIHRSCBV-XNBOLLIBSA-N 0.000 claims 5
- 102100035000 Thymosin beta-4 Human genes 0.000 claims 5
- 238000009472 formulation Methods 0.000 claims 5
- 108010079996 thymosin beta(4) Proteins 0.000 claims 5
- 150000001413 amino acids Chemical group 0.000 claims 4
- 239000002674 ointment Substances 0.000 claims 4
- 230000037394 skin elasticity Effects 0.000 claims 4
- 210000004899 c-terminal region Anatomy 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 102000001708 Protein Isoforms Human genes 0.000 claims 2
- 108010029485 Protein Isoforms Proteins 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 239000006071 cream Substances 0.000 claims 2
- 239000006185 dispersion Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000000499 gel Substances 0.000 claims 2
- 239000000017 hydrogel Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000011499 joint compound Substances 0.000 claims 2
- 239000006210 lotion Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000001737 promoting effect Effects 0.000 claims 2
- 239000007921 spray Substances 0.000 claims 2
- 150000003462 sulfoxides Chemical class 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- 108010046075 Thymosin Proteins 0.000 claims 1
- 102000007501 Thymosin Human genes 0.000 claims 1
- 230000001934 delay Effects 0.000 claims 1
- 230000035515 penetration Effects 0.000 claims 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29132601P | 2001-05-17 | 2001-05-17 | |
| PCT/US2002/015394 WO2002091969A1 (en) | 2001-05-17 | 2002-05-16 | Treating epidermlyosis bullosa with thymosin beta 4 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004525988A JP2004525988A (ja) | 2004-08-26 |
| JP2004525988A5 true JP2004525988A5 (enExample) | 2005-12-22 |
Family
ID=23119854
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002588889A Pending JP2004525988A (ja) | 2001-05-17 | 2002-05-16 | サイモシンβ４を用いる表皮水疱症（ＥｐｉｄｅｒｍｏｌｙｓｉｓＢｕｌｌｏｓａ）の治療 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1404268A4 (enExample) |
| JP (1) | JP2004525988A (enExample) |
| CN (1) | CN1241636C (enExample) |
| AU (1) | AU2002309842B2 (enExample) |
| CA (1) | CA2446072A1 (enExample) |
| MX (1) | MXPA03010446A (enExample) |
| WO (1) | WO2002091969A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007521336A (ja) * | 2003-12-22 | 2007-08-02 | リジェナークス・バイオファーマシューティカルズ・インコーポレイテッド | 反応性化学物質、生物学的物質、もしくは毒素に対する、生物学的もしくは免疫学的応答を、処理もしくは防止する方法 |
| EP2260106A4 (en) * | 2008-03-17 | 2011-04-20 | Regenerx Biopharmaceuticals | IMPROVED BETATHYMOSINFRAGMENTS |
| US8632827B2 (en) * | 2011-12-13 | 2014-01-21 | Avon Products, Inc | Modulation of thymosin beta-4 in skin |
| WO2014093053A1 (en) * | 2012-12-11 | 2014-06-19 | Avon Products, Inc. | Modulation of thymosin beta-4 in skin |
| CN104324279A (zh) * | 2014-11-19 | 2015-02-04 | 吕玲 | 一种治疗皮肤发育不良的中药药剂及制备方法 |
| WO2017214910A1 (zh) * | 2016-06-15 | 2017-12-21 | 石庆学 | 特异促进Tβ4基因高表达的慢病毒表达载体及其应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6087341A (en) * | 1998-02-12 | 2000-07-11 | The Board Of Trustees Of The Leland Standford Junior University | Introduction of nucleic acid into skin cells by topical application |
| EP2311485A1 (en) * | 1998-07-30 | 2011-04-20 | The Government of the United States of America, as represented by the Secretary of Health and Human Services | Thymosin beta 4 promotes wound repair |
-
2002
- 2002-05-16 CN CNB028100956A patent/CN1241636C/zh not_active Expired - Fee Related
- 2002-05-16 WO PCT/US2002/015394 patent/WO2002091969A1/en not_active Ceased
- 2002-05-16 JP JP2002588889A patent/JP2004525988A/ja active Pending
- 2002-05-16 EP EP02736866A patent/EP1404268A4/en not_active Withdrawn
- 2002-05-16 AU AU2002309842A patent/AU2002309842B2/en not_active Ceased
- 2002-05-16 CA CA002446072A patent/CA2446072A1/en not_active Abandoned
- 2002-05-16 MX MXPA03010446A patent/MXPA03010446A/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005502672A5 (enExample) | ||
| AU2002336408B2 (en) | Methods of healing or preventing inflammation, damage and other changes that occur prior to, during or immediately after a myocardial event with thymosin beta 4, analogues, isoforms and other derivatives | |
| KR970701776A (ko) | 형질전환 성장 인자 알파 에이치1(Transforming growth factor alpha H1) | |
| MXPA04009884A (es) | Uso de osteoprotegerina para el tratamiento y/o prevencion de enfermedad fibrotica. | |
| US20080286229A1 (en) | Method to promote hair growth and/or delay or treat hair loss by administering a tgf-beta antagonist or inhibitor | |
| JP2005506293A5 (enExample) | ||
| JP2004525988A5 (enExample) | ||
| CA2473996A1 (en) | Methods and compositions for the promotion of hair growth utilizing actin binding peptides | |
| JP2009046502A (ja) | 皮膚状態の改善を促進するための組成物の製造のための、アミノ酸配列ｌｋｋｔｅｔを含む皮膚変性阻害ポリペプチドの使用 | |
| US20100048474A1 (en) | Method of treating or preventing tissue deterioration, injury or damage due to periodontal disease or disease of oral mucosa, and/or downregulating nf-kappabeta or supressing nf-kappabeta-mediated actions | |
| US8716215B2 (en) | Method of treating or preventing tissue deterioration, injury or damage due to a neuro-, muscular- or neuro-muscular-degenerative disease, or restore tissue adversely affected by said disease | |
| CA2532542A1 (en) | Treatment or prevention of damage due to radiation exposure | |
| AU2004308378B2 (en) | Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agent | |
| JP2004527463A5 (enExample) | ||
| AU2002309842B2 (en) | Treating epidermlyosis bullosa with thymosin beta 4 | |
| JP2007521336A5 (enExample) | ||
| AU2002213513A1 (en) | Inhibition or reversal of skin aging by actin-sequestering peptides | |
| AU2002309842A1 (en) | Treating epidermlyosis bullosa with thymosin beta 4 | |
| US20040067227A1 (en) | Inhibition or reversal of skin aging by actin-sequestering peptides | |
| US20040170625A1 (en) | Methods of treating Epidermolysis Bullosa and associated dermatological indications with thymosin beta 4, analogues, isoforms and other derivatives | |
| MXPA06006849A (en) | Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agent | |
| KR20070019668A (ko) | 반응성 화학물질 또는 생물학적 물질 또는 독성 물질에대한 생물학적 또는 면역학적 반응들의 치료 또는 예방방법 | |
| HK1136216A (en) | Use of polypeptides for preparing medicines of promoting the transformation of cardiac endothelial cells to mesenchymal cells |